CAR T cells produced in vivo to treat cardiac injury
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We used an Ang II/PE infusion model to study cardiac fibrosis which has inherent limitations3,4,7,39”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances in CAR T-cell technology have provided a much needed breakthrough and indicated that selectively removing activated cardiac fibroblasts that express fibroblast activator protein (FAP) is sufficient to ameliorate fibrosis without impacting the structural integrity of the heart in preclinical mouse models 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have implicated a potential pathogenic role for FAP+ fibroblasts in mouse models of cardiac remodelling3,4.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“LNPs and CAR-T cells have been combined for antifibrotic therapy in experimental heart fibrosis by administering LNPs that reprogram host lymphocytes into CAR-T cells in order to target cardiac myofibroblasts that express fibroblast activation peptide alpha (FAP) (129).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have utilized chimeric antigen receptor (CAR) T cells to target FAP + fibroblasts in a mouse model of cardiac injury and shown improved cardiac function and diminished fibrosis 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Cited by
Items 501–600 of 1,001
Biologics and cardiac disease: challenges and opportunities
Ciucci, G., Colliva, A., Vuerich, R., Pompilio, G., & Zacchigna, S. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.06.001 · Cited by 20
Wakao, R., & Fukaya‐Shiba, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1141880 · Cited by 18
In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery
Henser‐Brownhill, T., Martin, L., Samangouei, P., Ladak, A., Apostolidou, M., Nagel, B., & Kwok, A. (2024) · Advanced Science · doi:10.1002/advs.202401935 · Cited by 20
Delehedde, C., Ciganek, I., Bernard, P.-L., Laroui, N., Silva, C. C. D., Gonçalves, C., Nunès, J. A., Griscelli, A. B., Imeri, J., Huyghe, M., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102263 · Cited by 18
mRNA‐Engineered CD5‐CAR‐γδTCD5‐ Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia
Zhu, Z., Li, H., Lu, Q., Zhang, Z., Li, J., Wang, Z., Yang, N., Yu, Z., Chen, Y., Chen, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202400024 · Cited by 23
The Future of CAR T Therapeutics to Treat Autoimmune Disorders
Pecher, A., Hensen, L., Lengerke, C., & Henes, J. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00730-0 · Cited by 18
Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies
Cheng, M. H. Y., Brimacombe, C. A., Verbeke, R., & Cullis, P. R. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00365 · Cited by 19
Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18
Qu, Y., Liu, R., Sun, D., & Dai, Z. (2024) · Materials Chemistry Frontiers · doi:10.1039/d4qm00479e · Cited by 22
Tonic signaling in CAR-T therapy: the lever long enough to move the planet
Huang, Y., & Wang, H. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1130-x · Cited by 20
In vivo production of CAR T cell: Opportunities and challenges
Song, Z., Zhou, Y., Wang, B., Geng, Y., Tang, G., Wang, Y., & Yang, J. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101612 · Cited by 29
Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond
Li, Y., Liu, Y., & Lin, X. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01304-8 · Cited by 18
Bioengineered microneedles and nanomedicine as therapeutic platform for tissue regeneration
Mao, Y.-A., Xu, S., Shi, X., Jin, Y., Pan, Z., Hao, T., Li, G., Chen, X., Wang, H., Wang, Y., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03623-4 · Cited by 20
Cancer-Related Immune Therapies
Miteva, K., Anker, M. S., Fechner, H., Lehmann, L., & Linthout, S. V. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.06.008 · Cited by 18
Co‐Delivery of Multiple RNAs via Lipid Nanoparticles Enables Precise Gene Editing of CAR‐T Cells
Wang, M., Liao, Q., Bai, S., Liu, X., Peng, Y., Liu, P., Lu, H., Zhu, J., & Zeng, C. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501475 · Cited by 22
Small-molecule control of CAR T cells
Adams, E. L., McGovern, A. C., So, V., Srinivasan, S., Deiters, A., & Lohmueller, J. J. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00768-6 · Cited by 21
Glycolipid nanoparticles target the spleen and detarget the liver without charge
Gentry, K., Lian, L., Kim, H., Celik, O., Jones, C., Podilapu, A. R., Shakked, A., Loughrey, D., Zenhausern, R., Jang, B., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409569122 · Cited by 18
In vivo nano-engineering T cells for CAR-T therapy
Shi, T., Li, Y., Deng, C., Ren, Q., Xu, C., & Zhong, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114379 · Cited by 20
Jain, M., Est-Witte, S. E., Shannon, S. R., Neshat, S. Y., Yu, X., Dunham, S., Tian, T. M., Cheng, L., Harris, J. J., Konig, M. F., et al. (2026) · Science Advances · doi:10.1126/sciadv.adz1722 · Cited by 19
Nie, X., Liu, Y., Song, Y., Yao, X., Chen, Y., Lee, H., & Gao, X. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ady6730 · Cited by 23
Xiao, Y., Feng, Q., Huang, L., Meng, X., Han, P., Zhang, W., & Kang, Y. J. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109180 · Cited by 17
Dalal, P., Patel, N. P., Feinstein, M. J., & Akhter, N. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221132927 · Cited by 17
The Tumor Microenvironment Reprograms Immune Cells
Cao, H., Gao, S., Jogani, R., & Sugimura, R. (2022) · Cellular Reprogramming · doi:10.1089/cell.2022.0047 · Cited by 19
Saraste, A., Knuuti, J. M., & Bengel, F. M. (2023) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jead128 · Cited by 17
Floris, E., Cozzolino, C., Marconi, S., Tonicello, F., Picchio, V., Pagano, F., & Chimenti, I. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2408226 · Cited by 20
Regulation of eDHFR-tagged proteins with trimethoprim PROTACs
Etersque, J. M., Lee, I. K., Sharma, N., Xu, K., Ruff, A., Northrup, J. D., Sarkar, S., Nguyen, T., Lauman, R., Burslem, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42820-3 · Cited by 18
SUZUKI, M. T., Mochida, Y., Hori, M., Hayashi, A., Toh, K., Tockary, T. A., Liu, X., Marx, V., Yokoo, H., Miyata, K., et al. (2024) · Small Science · doi:10.1002/smsc.202300258 · Cited by 18
Aguilar, S. V., Cui, M., Tan, W. H., Sanchez‐Ortiz, E., Bassel‐Duby, R., Liu, N., & Olson, E. N. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00447-7 · Cited by 20
Zheng, Y., Wang, Y., Qi, B., Lang, Y., Zhang, Z., Ma, J., Lou, M., Liang, X., Chang, Y., Zhao, Q., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368516 · Cited by 20
Fu, Z., Huang, Z., Xu, H., Liu, Q., Li, J., Song, K., Deng, Y., Tao, Y., Zhang, H., Wang, P., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178558 · Cited by 18
Xue, E., Minniti, A., Alexander, T., Papa, N. D., Greco, R., & on behalf of The Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2022) · Cells · doi:10.3390/cells11213346 · Cited by 18
New insights on potency assays from recent advances and discoveries in CAR T-cell therapy
Shao, L., Zheng, Y., Somerville, R. P. T., Stroncek, D. F., & Jin, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1597888 · Cited by 17
RNA–lipid nanoparticles for acute critical illnesses
Omo‐Lamai, S., Zamora, M. E., Mueller, B. K., Casciano, J. C., & Brenner, J. S. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00314-5 · Cited by 18
Albalawi, Y. A. (2025) · Medical Oncology · doi:10.1007/s12032-025-02928-6 · Cited by 17
Volta, L. G., & Gill, S. I. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100027 · Cited by 19
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 18
Engineering chimeric antigen receptor CD4 T cells for Alzheimer’s disease
Boskovic, P., Shalita, R., Gao, W., Vernon, H., Deng, Y. L., Colonna, M., Majzner, R. G., Amit, I., & Kipnis, J. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2530977123 · Cited by 20
Zhao, Y., Liu, C., Zhang, X., Gu, T., Wang, Y., Zuo, T., Liu, S., Xu, X., & Meng, H. (2026) · ACS Nano · doi:10.1021/acsnano.5c21857 · Cited by 19
Resetting autoimmune disease with CAR cell therapies
Schett, G. A., & Xu, H. (2026) · Nature Medicine · doi:10.1038/s41591-026-04430-6 · Cited by 19
Immune Cells in Cardiac Injury Repair and Remodeling
Zambrano, M. A., & Alcaide, P. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01854-1 · Cited by 18
Álvarez‐Benedicto, E., Tian, Z., Chatterjee, S., Orlando, D., Kim, M., Guerrero, E. D., Wang, X., & Siegwart, D. J. (2023) · Angewandte Chemie · doi:10.1002/ange.202310395 · Cited by 17
Song, H. W., Benzaoui, M., Dwivedi, A., Underwood, S., Shao, L., Achar, S. R., Posarac, V., Remley, V. A., Procházková, M., Cai, Y., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101171 · Cited by 20
Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration
Kishore, R., & Magadum, A. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11020038 · Cited by 22
CAR‐T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives
Abdalla, A. M. E., Yu, M., Ahmed, A. I. M., Meng, N., & Ouyang, C. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3955 · Cited by 16
Kushwaha, N., Panjwani, D., Patel, S., Ahlawat, P., Yadav, M. R., & Patel, A. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2417012 · Cited by 16
Manufacturing next-generation regulatory T-cell therapies
MacDonald, K. N., Salim, K., & Levings, M. K. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102822 · Cited by 17
Optimal delivery strategies for nanoparticle-mediated mRNA delivery
Li, X., Guo, X., Hu, M., Cai, R., & Chen, C. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02455a · Cited by 17
Regulatory circular RNAs in viral diseases: applications in diagnosis and therapy
Wang, W. J., Sun, L., Huang, M.-T., Quan, Y., Jiang, T., Miao, Z., & Zhang, Q. (2023) · RNA Biology · doi:10.1080/15476286.2023.2272118 · Cited by 16
Emerging mRNA therapies for cardiac fibrosis
Jardin, B. D., & Epstein, J. A. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00504.2023 · Cited by 16
Self-citationExploring the Potential and Advancements of Circular RNA Therapeutics
Wang, L., Wang, L., Dong, C., Liu, J., Cui, G., Gao, S., & Liu, Z. (2025) · Exploration · doi:10.1002/exp.20240044 · Cited by 21
Zheng, Q., Li, H., Jiang, Y., Yang, P., Yin, G., Yang, L., Li, S., & Sun, L. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114760 · Cited by 15
Recent Advances in mRNA Delivery Systems for Cancer Therapy
Zhang, Z., Fan, Y., Jiang, S., Ma, Y., Yu, Y., Qing, Y., Li, Q., Liu, Y., Shen, S., & Wang, J. (2025) · Advanced Science · doi:10.1002/advs.202417571 · Cited by 25
Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybrids for Drug Delivery
Chintapula, U. K., Liu, S., del Castillo, A. F., Lim, J., Roh, Y., Mageswaran, S. K., Zhang, X., Morales, R. T., Sellmyer, M. A., Chang, Y., et al. (2025) · Small · doi:10.1002/smll.202503807 · Cited by 15
Lai, M., Shao, W., Mao, J., & Ye, Q. (2025) · Research · doi:10.34133/research.0917 · Cited by 20
In Situ Chimeric Antigen Receptor Macrophage Therapy via Co-Delivery of mRNA and Immunostimulant
Han, J., Fagan, E., Yeom, K., & Park, J. (2025) · ACS Nano · doi:10.1021/acsnano.5c09138 · Cited by 17
The mRNA-Based Innovative Strategy: Progress and Challenges
Zhou, H., Wei, D., Chen, Z., Chen, H., Dong, C., Cai, W., Wang, J., Liu, X., Li, Y., Yang, Y., et al. (2026) · Nano-Micro Letters · doi:10.1007/s40820-025-01906-x · Cited by 24
Engineered immunosuppressive dendritic cells protect against cardiac remodelling
Li, X., Li, J., Li, G. G., Zhu, L., Guo, C., Li, H., Lin, H., Jia, N., Hong, X., Liu, Y., et al. (2026) · Nature · doi:10.1038/s41586-026-10346-5 · Cited by 25
Strategies for enhancing CAR T cell expansion and persistence in HIV infection
Rothemejer, F. H., Lauritsen, N. P., Søgaard, O. S., & Tolstrup, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1253395 · Cited by 17
Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies
Angelos, M. G., Patel, R. P., Ruella, M., & Barta, S. K. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.013 · Cited by 17
CAR T treatment beyond cancer: Hope for immunomodulatory therapy of non-cancerous diseases
Yang, Z., Liu, Y., & Hai, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122556 · Cited by 16
Hassanabad, A. F., Zarzycki, A. N., & Fedak, P. W. M. (2024) · Cardiovascular Pathology · doi:10.1016/j.carpath.2024.107635 · Cited by 20
Jiang, N., Zhao, K., Liu, C., Zhu, X., Huang, X., Yang, L., Yi, X., Zhuang, Y., Ye, B., Qian, J., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.150820 · Cited by 19
Niu, W., Wang, B., Zhang, Y., Wang, C., Cao, J., Li, J., He, Y., & Lei, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433679 · Cited by 18
Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects
George, C. A., Sahu, S. U., de Oñate, L., Souza, B. S. D. F., & Wilson, R. C. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0036 · Cited by 19
Non-viral vectors for chimeric antigen receptor immunotherapy
Tretbar, S., Rurik, J. G., Rustad, E. H., Sürün, D., Koehl, U., Olweus, J., Buchholz, F., Ivics, Z., Fricke, S., & Blache, U. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00348-w · Cited by 16
Self-citationRigau, A. R., Liang, M., Devakumar, V., Neelagar, R., Matei, A., Györfi, A., Bergmann, C., Filla, T., Fedorchenko, V., Schett, G. A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-226336 · Cited by 20
Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells
Zhang, Q., Dai, J., Liu, T., Rao, W., Li, D., Gu, Z., Huang, L., Wang, J., & Hou, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05134-6 · Cited by 15
Lipid nanoparticles: A delicate nucleic acid delivery system to be further explored
Ma, R., Li, Y., Su, Y., Chen, P., Xie, S., Tan, W., & Liu, X. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102586 · Cited by 15
Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV
Bowden-Reid, E., Moles, E., Kelleher, A. D., & Ahlenstiel, C. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01788-x · Cited by 16
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases
Huang, Q., Zhu, X., & Zhang, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00736-8 · Cited by 16
Lipid nanoparticles for mRNA therapy: recent advances in targeted delivery
Wei, T., Tao, W., & Cheng, Q. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac004 · Cited by 16
Prospective therapeutics for intestinal and hepatic fibrosis
Li, X., Yu, M., Zhao, Q. D., & Yu, Y. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10579 · Cited by 15
Making the Next Generation of Therapeutics: mRNA Meets Synthetic Biology
Hınçer, A., Ahan, R. E., Aras, E., & Şeker, U. Ö. Ş. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00253 · Cited by 16
Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure
Amrute, J. M., Luo, X., Penna, V., Bredemeyer, A., Yamawaki, T., Heo, G. S., Shi, S., Koenig, A., Yang, S., Kadyrov, F., et al. (2022) · bioRxiv · doi:10.1101/2022.10.17.512579 · Cited by 14
Lipid nanoparticles for engineering next generation CAR T cell immunotherapy
Ang, M. J. Y., Metzloff, A. E., Thatte, A. S., & Mitchell, M. J. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00432b · Cited by 20
Fang, X., Yan, S., He, L., & Deng, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1735763 · Cited by 17
Engineered Regulatory T Lymphocytes Promote Infarcted Heart Repair
Zhang, M., Qin, Y., Zhou, T., Liu, M., Tang, T. A., Xia, N., Nie, S., Lv, B., Zhu, Z., Jiao, J., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.076321 · Cited by 20
Non-viral delivery of RNA for therapeutic T cell engineering
Berdecka, D., Smedt, S. C. D., Vos, W. H. D., & Braeckmans, K. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115215 · Cited by 15
Leveraging high-throughput screening technologies in targeted mRNA delivery
Zhang, Y., Gao, Z., Yang, X. Q., Xu, Q., & Lu, Y. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101101 · Cited by 20
Tuning CAR T-cell therapies for efficacy and reduced toxicity
Blud, D., Reyes, P. R., Perret, R., & Weinkove, R. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.07.003 · Cited by 14
Multiple tail ionizable lipids improve in vivo mRNA delivery efficiency with biosafety
Liu, C., Jiang, Y., Xue, W., Liu, J., Wang, Z., & Li, X. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124868 · Cited by 17
Wang, S.-Y., An, W.-H., Wang, Z., Wang, W.-L., Zhang, B., Xu, K., Guo, S., Gao, M., Li, B., Huang, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418768 · Cited by 15
Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy
Gu, R., Shen, J., Zhang, J., Mao, J., & Ye, Q. (2025) · Research · doi:10.34133/research.0712 · Cited by 17
Li, Z., Yang, F., Wu, X., Wu, X., Li, S., & Wang, M. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217928 · Cited by 19
Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir
Choudhary, M. C., Cyktor, J. C., & Riddler, S. A. (2022) · Journal of Virus Eradication · doi:10.1016/j.jve.2022.100073 · Cited by 15
Non-coding RNAs: Important participants in cardiac fibrosis
Dong, Y., Peng, N., Dong, L., Tan, S., & Zhang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.937995 · Cited by 15
Potential roles of hyaluronic acid in in vivo CAR T cell reprogramming for cancer immunotherapy
Laomeephol, C., Areecheewakul, S., Tawinwung, S., Suppipat, K., Chunhacha, P., Neves, N. M., & Luckanagul, J. A. (2022) · Nanoscale · doi:10.1039/d2nr05949e · Cited by 14
Cardiac Applications of Fibroblast Activation Protein Imaging
Diekmann, J., & Bengel, F. M. (2023) · PET Clinics · doi:10.1016/j.cpet.2023.03.004 · Cited by 14
Nanotechnology-based drug delivery strategies for cancer therapy
Xu, Y., Ren, X., Yu, M., Weng, Y., Liu, Y., Song, B., Niu, J., Qiao, Z., Lin, Y., Cao, Y., et al. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0802 · Cited by 20
The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases
Shu, J., Xie, W., Chen, Z., Offringa, R., Hu, Y., & Mei, H. (2024) · Med · doi:10.1016/j.medj.2024.03.016 · Cited by 16
Applications of CRISPR technology in cellular immunotherapy
Zhou, X., Renauer, P. A., Zhou, L., Fang, S., & Chen, S. (2023) · Immunological Reviews · doi:10.1111/imr.13241 · Cited by 14
Bispecific antibody targeting of lipid nanoparticlesPreprint
Amabile, A., Phelan, M., Yu, Z., Silva, P., Marks, A. R., Morlà‐Folch, J., Sohn, M., Mollaoglu, G., Falcomatà, C., Teunissen, A. J. P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.20.629467 · Cited by 15
Yashaswini, C. N., Cogliati, B., Qin, T., To, T., Williamson, T., Papp, T. E., Li, K., Rasul, R., Chen, L., Lightstone, A., et al. (2025) · doi:10.1101/2025.02.25.640143 · Cited by 13
Self-citationXu, X., Cui, L., Zhang, Y., & Gu, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.023 · Cited by 13
“For instance, CD5 antibody-conjugated LNPs enable efficient mRNA delivery to T lymphocytes, driving robust in vivo generation of functional CAR T cells 209 .”
SMAD7: riding on fibrosis-limiting routes and beyond
Martin, L., Gabbiani, G., & Meyer, G. R. Y. D. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00283-7 · Cited by 17
Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation
Kim, C., Lee, Y., Lee, H., & Kim, B. (2025) · Small Methods · doi:10.1002/smtd.202501401 · Cited by 14
TCRdesign: an antigen-specific generative language model for de novo design of T-cell receptors
Li, X., Yang, Q., Xu, L., Dong, W., Wang, K., Dong, S., Wang, W., Luo, G., Zhang, X., Yang, T., et al. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf691 · Cited by 19
Bengel, F. M., Hess, A., Diekmann, J., & Thackeray, J. T. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01242-y · Cited by 16
Zhang, Z., Cui, D., Wang, H., Wu, L., & Liu, X. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04278-8 · Cited by 16
In Vivo CAR-T Therapies—A New Era of Programmable Immunity
Pierini, S., Qureshi, R., Pustylnikov, S., Bartosh, Z., & Akimova, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041737 · Cited by 15
Metadata
- Authors
- Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., Mui, B. L., Albelda, S. M., Puré, E., June, C. H., Aghajanian, H., Weissman, D., Parhiz, H., & Epstein, J. A.
- Affiliations
- University of Pennsylvania (US)
- Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics (Canada) (CA)
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Corresponding author
- Tombácz, István
- Yadegari, Amir
- Aghajanian, Haig
- Weissman, Drew
- Parhiz, Hamideh
- Epstein, Jonathan A.
- ORCID
- Venue
- Science
- Published
- 2022-01-07
- Volume
- 375
- Issue
- 6576
- Pages
- 91-96
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9983611
- OpenAlex
- W4206716689
- Cited by
- 1,400
- References
- 36
- Citations by year
- 2026: 375 · 2025: 348 · 2024: 312 · 2023: 215 · 2022: 148
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL134839, R35HL140018)
- National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- chimeric antigen receptor T cells, myocardial fibrosis, heart failure, lipid nanoparticles, mRNA delivery, antifibrotic therapy, trogocytosis, cardiac injury
- MeSH terms
- Receptors, Chimeric Antigen, Trogocytosis, Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Fibrosis, Heart Diseases, Heart Failure, Humans, Liposomes, Male, Membrane Proteins, Mice, Inbred C57BL, Myocardium, Endopeptidases, RNA, Messenger, Spleen, T-Lymphocytes, Immunotherapy, Adoptive, CD5 Antigens, Adoptive Transfer, Mice, Nanoparticles, HEK293 Cells, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.